Growth hormone hypersecretion in a girl with McCune-Albright syndrome: comparison with controls and response to a dose of long-acting somatostatin analog.

1995 ◽  
Vol 80 (4) ◽  
pp. 1357-1360
Author(s):  
P P Feuillan ◽  
J Jones ◽  
J L Ross
Keyword(s):  
Growth Hormone ◽  
Somatostatin Analog ◽  
Mccune Albright Syndrome ◽  
Albright Syndrome ◽  
Long Acting ◽  
Mccune Albright

scholarly journals Pegvisomant for the Treatment of gsp-Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome

2006 ◽  
Vol 91 (8) ◽  
pp. 2960-2966 ◽  
Author(s):  
Sunday O. Akintoye ◽  
Marilyn H. Kelly ◽  
Beth Brillante ◽  
Natasha Cherman ◽  
Sarah Turner ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Mccune Albright Syndrome ◽  
Albright Syndrome ◽  
Mccune Albright

scholarly journals Case Study of a 15-Year-old Boy with McCune-Albright Syndrome Combined with Pituitary Gigantism: Effect of Octreotide-long Acting Release (LAR) and Cabergoline Therapy

2008 ◽  
Vol 55 (3) ◽  
pp. 595-599 ◽  
Author(s):  
Toshihiro TAJIMA ◽  
Junko TSUBAKI ◽  
Katsura ISHIZU ◽  
Wakako JO ◽  
Nobuaki ISHI ◽  
...  
Keyword(s):  
Mccune Albright Syndrome ◽  
Albright Syndrome ◽  
Long Acting ◽  
Mccune Albright

scholarly journals McCune-albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin - case report

2009 ◽  
Vol 53 (1) ◽  
pp. 102-106 ◽  
Author(s):  
João Paulo C. Almeida ◽  
Lucas Alverne F. Albuquerque ◽  
Camila L. H. Ferraz ◽  
Ítalo Mota ◽  
Jackson Gondim ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Bone Growth ◽  
Tolerance Test ◽  
Hormonal Control ◽  
Oral Glucose ◽  
Mccune Albright Syndrome ◽  
Albright Syndrome ◽  
Long Acting ◽  
The Right ◽  
Mccune Albright

OBJECTIVES: The use of drug therapy based on cabergoline, octreotide and long-acting release (LAR) octreotide has presented varying results in the treatment of GH excessive production in patients with McCune-Albright Syndrome. METHODS: We report the case of a 29 year-old female patient presenting McCune-Albright Syndrome and complaint of excessive bone growth. RESULTS: The patient presented a pituitary adenoma involving the right internal carotid artery and excessive secretion of growth hormone (no GH suppression was observed after the oral glucose tolerance test). Due to the presence of diffuse thickness in skull base bones, surgical approach was not considered effective and the patient was submitted to drug therapy with octreotide LAR and cabergoline. At the one year follow-up, GH and IGF-1 levels were normal and no adverse effects were present. CONCLUSION: The use of drug therapy based on the association of cabergoline and octreotide is safe and able to achieve complete hormonal control in the treatment of acromegaly for McCune-Albright patients.

Sign in / Sign up

Export Citation Format

Share Document